Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade

International Surgery

Volumn 95, Issue 1, 2010, Pages 67-75

  Wolfort, R M ^a   Papillion, P W ^a   Turnage, R H ^a   Lillien, D L ^b   Ramaswamy, M R ^b   Zibari, G B ^a  

^a Department of Surgery Hepafobiliary and Liver Transplant Surgery   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ARTICLE; BLOOD; CANCER STAGING; CELL DIFFERENTIATION; COMPARATIVE STUDY; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77952798063     PISSN: 00208868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003;226: 533-542.
2. Lee JD, Yun M, Lee JM, Choi Y, Choi YH, Kim JS et al. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 2004;31:1621-1630.
3. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V et al. Flourine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94:3314-3319.
4. Iwata Y, Shiomi S, Sasaki N, Jomura H, Nishiguchi S, Seki S et al. Clinical usefulness of positron emission tomography with fluolorine-18- fluorodexoyglucose in the diagnosis of liver tumors. Ann Nucl Med 2000;14:121-126.
5. Bohm B, Voth M, Geoghegan J, Hellfritzsch H, Petrovich A, Scheele J et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 2004;130:266-272.
6. Shiomi S, Nishiguchi S, Ishizu H, Iwata Y, Sasaki N, Tamori A et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001;96:1877-1880.
7. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J NucI Med 1995;36:1811-1817.
8. Wudel LJ Jr, Delbeke D, Morris D, Rice M, Washington MK, Shyr Y et al. The role of 18F-fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003;69:117-124.
9. Giannopoulou C. The role SPET and PET in monitoring tumor response to therapy. Eur J Nucl Med 2003;30:1173-1200.
10. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H et al. Positron emission tomography in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32: 792-797.
11. Tucker R, Coel M, Ko J, Morris P, Druger G, McGuigan P. Impact of fluorine-18-fluorodeoxyglucose positron emission tomography on patient management first year's experience in a clinical center.J Clin Oncol 2001;19:2504-2508.
12. Sugiyama M, Sakahara H, Torizuka T, Kanno T, Nakamura F, Futatsubashi M et al. 18F-FDG PET in the detection of extrahepatic metastasis from hepatocellular carcinoma. J Gastroenterol 2004;39:961-968.
13. Shang JB, Li YH, Liu FY, Zeng QL, Wang JY, He XF et al. 18-fluorodeoxyglucose uptake in hepatocellular carcinoma on positron emission tomography correlates with alpha-fetoprotein. Di Yi Jun Yi Da Xue Xue Bao 2004;24:697-699.
14. Boykin KN, Zibari GB, Lilien DL, McMillan RW, Aultman DF, McDonald JC. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver. Am Surg 1999;65:1183-1185.
15. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-1674.
16. Hain SF, Fogleman I. Recent advances in imaging hepatocellular carcinoma: diagnosis, staging, and response assessment Functional imagining. Cancer J 2004;10:121-127.
17. Liangpunsakul S, Agarwal D, Horlander JC, Kieff B, Chalasani N. Positron emission tomography for detecting occult hepatocellular carcinoma in hepatitis cirrhosis awaiting liver transplantation. Transplant Proc 2003;35:2995-2997.
18. Jeng LB, Changlai SP, Shen YY, Lin CC, Tsai CH, Kao CH. Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers. Hepatogastroenterology 2003;50:2154-2156.